170 related articles for article (PubMed ID: 2936838)
1. Endogenous thymidine and hypoxanthine are a source of error in evaluating methotrexate cytotoxicity by clonogenic assays using undialyzed fetal bovine serum.
Sobrero AF; Bertino JR
Int J Cell Cloning; 1986 Jan; 4(1):51-62. PubMed ID: 2936838
[TBL] [Abstract][Full Text] [Related]
2. Critical modulation by thymidine and hypoxanthine of sequential methotrexate-5-fluorouracil synergism in murine L1210 cells.
Piper AA; Nott SE; Mackinnon WB; Tattersall MH
Cancer Res; 1983 Nov; 43(11):5101-5. PubMed ID: 6616448
[TBL] [Abstract][Full Text] [Related]
3. Osteosarcoma cells, resistant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs.
Cole PD; Smith AK; Kamen BA
Cancer Chemother Pharmacol; 2002 Aug; 50(2):111-6. PubMed ID: 12172974
[TBL] [Abstract][Full Text] [Related]
4. The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides.
Pinedo HM; Zaharko DS; Bull JM; Chabner BA
Cancer Res; 1976 Dec; 36(12):4418-24. PubMed ID: 1087180
[TBL] [Abstract][Full Text] [Related]
5. Antifolate pseudo-resistance due to elevated levels of thymidine and hypoxanthine in a commercial serum preparation.
Simon M; Blatter J; Granzow C
Anticancer Res; 2007; 27(2):769-73. PubMed ID: 17465201
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells.
Smith SG; Lehman NL; Moran RG
Cancer Res; 1993 Dec; 53(23):5697-706. PubMed ID: 8242626
[TBL] [Abstract][Full Text] [Related]
7. Role of culture conditions and exposure duration in determining sensitivity of human bone marrow progenitor cells to methotrexate.
Umbach GE; Spitzer G; Ajani JA; Hug V; Thames H; Rudolph FB; Drewinko B
J Cancer Res Clin Oncol; 1986; 111(3):273-6. PubMed ID: 3733857
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate cytotoxicity in cultured human leukemic cells studied by flow cytometry.
Taylor IW; Tattersall MH
Cancer Res; 1981 Apr; 41(4):1549-58. PubMed ID: 6163527
[TBL] [Abstract][Full Text] [Related]
9. Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro.
Fabre I; Fabre G; Goldman ID
Cancer Res; 1984 Aug; 44(8):3190-5. PubMed ID: 6204743
[TBL] [Abstract][Full Text] [Related]
10. Comparison of thymidine and folinic acid protection from methotrexate toxicity in human lymphoid cell lines.
Browman GP
Cancer Treat Rep; 1982 Dec; 66(12):2051-9. PubMed ID: 6982753
[TBL] [Abstract][Full Text] [Related]
11. Effect of methotrexate on murine bone marrow cells in vitro: evidence of a reversible antiproliferative action.
Strømhaug A; Warren DJ; Slørdal L
Exp Hematol; 1995 May; 23(5):439-43. PubMed ID: 7720815
[TBL] [Abstract][Full Text] [Related]
12. Reversal of methotrexate inhibition of colony growth of L1210 leukemia cells in semisolid medium.
Nederbragt H; Uitendaal MP; van der Grint L; Leyva A; Pinedo HM
Cancer Res; 1981 Mar; 41(3):1193-8. PubMed ID: 6970074
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of methotrexate-induced differentiation of cultured human choriocarcinoma (BeWo) cells by thymidine.
Burres NS; Cass CE
Cancer Res; 1987 Oct; 47(19):5059-64. PubMed ID: 3497716
[TBL] [Abstract][Full Text] [Related]
14. Azidothymidine and dipyridamole as biochemical response modifiers: synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells.
Zhen YS; Taniki T; Weber G
Oncol Res; 1992; 4(2):73-8. PubMed ID: 1596584
[TBL] [Abstract][Full Text] [Related]
15. Thymidine and hypoxanthine requirements of normal and malignant human cells for protection against methotrexate cytotoxicity.
Howell SB; Mansfield SJ; Taetle R
Cancer Res; 1981 Mar; 41(3):945-50. PubMed ID: 6257387
[No Abstract] [Full Text] [Related]
16. Inability of leucovorin to rescue a naturally methotrexate-resistant human soft tissue sarcoma cell line from trimetrexate cytotoxicity.
Li WW; Bertino JR
Cancer Res; 1992 Dec; 52(24):6866-70. PubMed ID: 1458475
[TBL] [Abstract][Full Text] [Related]
17. Establishment of methotrexate-resistant human acute lymphoblastic leukemia cells in culture and effects of folate antagonists.
Ohnoshi T; Ohnuma T; Takahashi I; Scanlon K; Kamen BA; Holland JF
Cancer Res; 1982 May; 42(5):1655-60. PubMed ID: 6978176
[TBL] [Abstract][Full Text] [Related]
18. Implications for improved high-dose methotrexate therapeutic effects in cultured human breast cancer and bone marrow cells.
Bowen D; Southerland WM; Johnson DH; Hawkins M; Hughes DE
Cancer Detect Prev; 2000; 24(5):452-8. PubMed ID: 11129987
[TBL] [Abstract][Full Text] [Related]
19. Effects of methotrexate and of the "nonclassical" folate antagonist trimetrexate on human leukemia cells.
Rodenhuis S; McGuire JJ; Sawicki WL; Bertino JR
Leukemia; 1987 Feb; 1(2):116-20. PubMed ID: 2959824
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of folinic acid and glycine, adenosine, and thymidine as rescue agents in methotrexate-treated human cells in relation to the accumulation of methotrexate polyglutamates.
Rosenblatt DS; Whitehead VM; Matiaszuk NV; Pottier A; Vuchich MJ; Beaulieu D
Mol Pharmacol; 1982 May; 21(3):718-22. PubMed ID: 6180291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
